The estimated Net Worth of Paul A Foster is at least $1.08 Million dollars as of 17 September 2018. Paul Foster owns over 40,000 units of Xencor Inc stock worth over $949,836 and over the last 11 years Paul sold XNCR stock worth over $130,681.
Paul has made over 10 trades of the Xencor Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Paul exercised 40,000 units of XNCR stock worth $442,000 on 17 September 2018.
The largest trade Paul's ever made was exercising 40,000 units of Xencor Inc stock on 17 September 2018 worth over $442,000. On average, Paul trades about 7,087 units every 63 days since 2014. As of 17 September 2018 Paul still owns at least 44,952 units of Xencor Inc stock.
You can see the complete history of Paul Foster stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA, CA, 91016.
Over the last 11 years, insiders at Xencor Inc have traded over $93,804,287 worth of Xencor Inc stock and bought 1,139,502 units worth $15,515,932 . The most active insiders traders include Capital, Llcstafford John S..., John S Iii Stafford, and John S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of $779,296. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth $536,500.
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
Xencor Inc executives and other stock owners filed with the SEC include: